KRN-101

KRN-101 is a pharmaceutical-grade natural psilocybin product developed by Albert Labs. It is derived from psilocybin-producing mycelium using a proprietary, patent-pending bioreactor technology designed to ensure consistent, high-quality production of the active pharmaceutical ingredient (API). KRN-101 is intended for use in conjunction with psychotherapy to treat mental health conditions, with a primary focus on cancer-related distress, including anxiety and depression. As a tryptamine alkaloid, it functions as a serotonin receptor agonist, primarily targeting the 5-HT2A receptor to induce therapeutic effects. The company utilizes a Real-World Evidence (RWE) clinical trial framework to accelerate regulatory approval and patient access in the UK and North American markets.

Other names

natural psilocybin